Medico Remedies (MEDICO)₹18.88−0.53%Pharmaceuticals
In the Mar 2026 quarter (standalone), Medico Remedies reported sales of ₹56.87 Cr, up 37.4% from Mar 2025, and net profit of ₹5.87 Cr, up 34.9% year on year. For the year to Mar 2026, sales were ₹206 Cr and net profit ₹13.03 Cr.
Company filings, standalone accounts; latest reported quarter Mar 2026
| Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 31.51 | 42.44 | 29.80 | 41.38 | 30.86 | 39.40 | 39.54 | 41.40 | 38.30 | 52.69 | 58.77 | 56.87 |
| Expenses | 29.06 | 39.31 | 27.06 | 36.72 | 28.02 | 37.00 | 36.43 | 34.70 | 35.45 | 49.95 | 54.41 | 49.75 |
| Operating Profit | 2.47 | 3.08 | 2.74 | 4.66 | 2.83 | 2.42 | 3.12 | 6.68 | 2.83 | 2.74 | 4.34 | 7.16 |
| OPM % | 7.9% | 7.3% | 9.2% | 11.3% | 9.2% | 6.1% | 7.9% | 16.2% | 7.4% | 5.2% | 7.4% | 12.6% |
| Other Income | 0.30 | 0.95 | 0.26 | 0.57 | 0.28 | 0.67 | 1.42 | 0.28 | 0.65 | 1.71 | 0.67 | 2.86 |
| Interest | 0.16 | 0.17 | 0.21 | 0.24 | 0.17 | 0.20 | 0.27 | 0.48 | 0.27 | 0.23 | 0.38 | 0.89 |
| Depreciation | 0.72 | 0.72 | 0.73 | 0.75 | 0.76 | 0.76 | 0.77 | 0.78 | 0.78 | 0.74 | 0.80 | 0.81 |
| Profit before tax | 1.90 | 3.15 | 2.07 | 4.25 | 2.19 | 2.14 | 3.51 | 5.70 | 2.44 | 3.49 | 3.84 | 8.33 |
| Tax % | 29.6% | 22.6% | 30.1% | 26.9% | 27.0% | 27.2% | 25.1% | 23.9% | 25.5% | 25.8% | 25.0% | 29.6% |
| Net Profit | 1.33 | 2.44 | 1.46 | 3.11 | 1.59 | 1.56 | 2.63 | 4.35 | 1.83 | 2.58 | 2.88 | 5.87 |
| EPS (Rs) | 0.17 | 0.30 | 0.18 | 0.38 | 0.20 | 0.20 | 0.33 | 0.53 | 0.23 | 0.32 | 0.36 | 0.72 |
| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 67.11 | 54.06 | 61.07 | 98.15 | 89.18 | 122 | 121 | 140 | 145 | 151 | 206 | 207 |
| Expenses | 63.06 | 50.04 | 58.08 | 95.06 | 86.11 | 117 | 114 | 131 | 132 | 136 | 189 | 190 |
| Operating Profit | 4.01 | 4.01 | 3.01 | 3.01 | 3.01 | 5.01 | 7.01 | 10.03 | 13.02 | 15.03 | 17.03 | 17.07 |
| OPM % | 5.0% | 7.0% | 6.0% | 2.8% | 3.2% | 4.3% | 6.0% | 7.0% | 9.1% | 10.0% | 8.0% | 8.3% |
| Other Income | 0.00 | 0.00 | 0.99 | 1.99 | 1.99 | 0.99 | 1.99 | 3.99 | 1.99 | 2.99 | 5.99 | 5.89 |
| Interest | 0.99 | 0.99 | 1.99 | 0.99 | 0.99 | 0.99 | 0.99 | 0.99 | 0.99 | 0.99 | 1.99 | 1.77 |
| Depreciation | 1.01 | 1.01 | 1.01 | 2.01 | 2.01 | 2.01 | 2.01 | 3.01 | 3.01 | 3.01 | 3.01 | 3.13 |
| Profit before tax | 2.01 | 2.01 | 2.01 | 2.01 | 2.01 | 4.01 | 6.01 | 10.02 | 11.02 | 14.03 | 18.03 | 18.10 |
| Tax % | 40.0% | 4.0% | 35.0% | 28.0% | 26.0% | 30.0% | 26.0% | 28.0% | 27.0% | 25.0% | 26.9% | — |
| Exceptional items | 0.00 | −0.19 | 0.00 | 0.00 | 0.00 | 0.00 | −0.04 | 0.00 | 0.00 | 0.00 | 0.00 | — |
| Net Profit | 1.01 | 2.01 | 1.01 | 2.01 | 2.01 | 3.01 | 5.01 | 7.02 | 8.02 | 10.03 | 13.03 | 13.16 |
| EPS (Rs) | 0.36 | 0.26 | 0.16 | 0.20 | 0.21 | 0.32 | 0.59 | 0.88 | 1.01 | 1.23 | 1.59 | 1.63 |
| Dividend payout % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 2.01 | 2.01 | 3.01 | 4.01 | 4.01 | 4.01 | 4.01 | 17.04 | 17.03 | 17.05 | 17.07 | 17.07 |
| Reserves | 11.99 | 13.01 | 13.02 | 23.01 | 23.98 | 25.97 | 27.96 | 19.98 | 26.96 | 35.94 | 45.97 | 58.98 |
| Borrowings | 7.99 | 13.99 | 19.02 | 13.00 | 13.99 | 13.98 | 14.98 | 12.97 | 9.97 | 7.99 | 14.99 | 18.98 |
| Other Liabilities | 14.07 | 17.08 | 13.06 | 20.10 | 35.17 | 32.16 | 28.14 | 28.14 | 34.17 | 36.17 | 43.20 | 59.28 |
| Total Liabilities | 36.06 | 46.09 | 48.11 | 59.12 | 76.15 | 75.12 | 76.09 | 77.13 | 87.13 | 96.15 | 120 | 153 |
| Fixed Assets | 7.98 | 6.99 | 6.99 | 6.98 | 11.98 | 12.97 | 14.96 | 17.97 | 21.96 | 20.96 | 20.97 | 19.95 |
| CWIP | 0.00 | 0.00 | 2.99 | 3.99 | 0.99 | 2.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 3.01 |
| Investments | 1.01 | 1.01 | 0.00 | 0.00 | 0.00 | 0.00 | 1.01 | 0.00 | 1.01 | 2.01 | 2.01 | 2.01 |
| Other Assets | 27.07 | 38.09 | 39.13 | 48.15 | 63.18 | 60.14 | 59.12 | 59.16 | 64.16 | 73.18 | 96.25 | 129 |
| Inventories | 8.01 | 9.02 | 10.03 | 15.03 | 16.03 | 18.05 | 15.03 | 18.03 | 20.04 | 16.03 | 27.06 | 30.08 |
| Trade receivables | 7.01 | 20.05 | 18.02 | 17.02 | 29.06 | 24.05 | 27.05 | 30.05 | 36.07 | 50.08 | 57.06 | 82.10 |
| Cash & equivalents | 1.99 | 0.99 | 0.99 | 0.99 | 0.99 | 0.99 | 2.99 | 1.99 | 0.99 | 0.00 | 0.99 | 1.99 |
| Total Assets | 36.06 | 46.09 | 48.11 | 59.12 | 76.15 | 75.12 | 76.09 | 77.13 | 87.13 | 96.15 | 120 | 153 |
| Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operating activity | −3.01 | 5.01 | 5.01 | 1.01 | −11.04 | 6.01 | 8.03 | 2.01 | 5.01 | 6.02 |
| Cash from investing activity | −3.01 | −5.01 | −4.01 | −3.01 | −17.03 | −2.01 | −7.02 | −3.01 | −3.01 | −5.01 |
| Cash from financing activity | 5.99 | −0.99 | −0.99 | 2.99 | 17.97 | −5.99 | −1.99 | 0.00 | −0.99 | −0.99 |
| Net cash flow | 0.00 | 0.00 | 0.00 | 0.00 | −10.01 | −2.01 | 0.00 | −1.01 | 1.01 | 1.01 |
| Capex | 0.82 | 2.41 | 2.80 | 1.95 | 16.99 | 0.00 | 0.00 | 0.00 | 0.00 | 4.50 |
| Free cash flow | −3.99 | 2.99 | 0.99 | −1.99 | −27.95 | 2.99 | 1.99 | 0.00 | 1.99 | 0.99 |
| CFO / OP % | −67.9% | 162.1% | 198.0% | 53.1% | −198.0% | 104.1% | 111.1% | 43.0% | 58.1% | 64.0% |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor days | 53 | 107 | 122 | 102 | 109 | 98 | 82 | 92 | 94 | 125 | 138 | 145 |
| Inventory days | 75 | 62 | 95 | 124 | 73 | 98 | 57 | 75 | 68 | 53 | 89 | 71 |
| Days payable | 122 | 106 | 112 | 147 | 149 | 143 | 100 | 113 | 108 | 105 | 117 | 119 |
| Cash conversion cycle | 6 | 64 | 105 | 80 | 33 | 54 | 39 | 54 | 54 | 75 | 111 | 98 |
| Working capital days | 21 | 53 | 110 | 88 | 49 | 61 | 50 | 52 | 54 | 74 | 90 | 87 |
| ROCE % | 10.1% | 11.1% | 10.1% | 9.0% | 8.0% | 8.0% | 10.0% | 15.1% | 21.0% | 21.1% | 21.1% | 23.1% |
For the Mar 2026 quarter, Medico Remedies reported sales of ₹56.87 Cr, up 37.4% year on year and net profit of ₹5.87 Cr, up 34.9% year on year. The operating margin was 12.6%.
Medico Remedies' sales for the year to Mar 2026 were ₹206 Cr; over the last twelve months they were ₹207 Cr.
Net profit for the year to Mar 2026 was ₹13.03 Cr, and ₹13.16 Cr over the last twelve months. Earnings per share over the same trailing period were ₹1.63.
Medico Remedies reported borrowings of ₹18.98 Cr at Mar 2026, against cash and equivalents of ₹1.99 Cr.
Cash from operations was ₹6.02 Cr in the year to Mar 2026; after capital spending, free cash flow was ₹0.99 Cr.